Introduction {#Sec1}
============

With 8.7 million deaths (16% of all deaths), cancer was globally the second-leading cause of death behind cardiovascular diseases in 2015 (GBD 2015 Mortality and Causes of Death Collaborators [@CR12]). There were 17.5 million incident cases globally, and cancer accounted for 209 million DALYs (GBD 2015 DALYs and HALE Collaborators [@CR10]; GBD 2015 Disease and Injury Incidence and Prevalence Collaborators [@CR11]; Global Burden of Disease Cancer Collaboration et al. [@CR14]). In many countries, the epidemiological transition has led to a decrease in communicable, neonatal, maternal, and nutritional diseases, at the expense of an increase in non-communicable diseases over time (GBD 2015 DALYs and HALE Collaborators [@CR10]). Prior studies examining cancer epidemiology in the EMR have either focused on a single year, a single country, or a particular component of cancer treatment (Aljurf et al. [@CR4]; Abdel-Razeq et al. [@CR1]; Kulhánová et al. [@CR19]). What has not been analyzed for the EMR is how the epidemiological and demographical transition through an aging population, urbanization, industrialization, and lifestyle changes, as well political turmoil has affected the cancer burden (GBD 2015 DALYs and HALE Collaborators [@CR10]). This evidence is essential for comprehensive cancer control planning. Given the diverse country profiles in the EMR with large differences in income, age structure, risk factor profile, and political stability, cancer prevention potential and treatment capacity requirements differ substantially between countries. In this study, we therefore present the Global Burden of Disease Study 2015 (GBD 2015) estimates of incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and DALYs for 29 cancer groups and 22 EMR countries from 2005 to 2015 by age and sex, which to our knowledge is the most comprehensive assessment of cancer burden in the EMR (GBD 2015 DALYs and HALE Collaborators [@CR10]; GBD 2015 Disease and Injury Incidence and Prevalence Collaborators [@CR11]; GBD 2015 Mortality and Causes of Death Collaborators [@CR12]; GBD 2015 Risk Factors Collaborators [@CR13]). This quantitative assessment is especially important to guide health policy and to measure progress on the third Sustainable Development Goal (SDG) of reducing premature mortality from non-communicable diseases by one third by 2030 (United Nations [@CR28]).

Methods {#Sec2}
=======

The GBD 2015 study estimated incidence, prevalence, deaths, YLLs, YLDs, and DALYs for 195 countries and territories from 1990 to 2015. In total, 315 causes of diseases and injuries and 79 risk factors were systematically analyzed. Details of the methodology used in GBD 2015 to estimate general disease burden and cancer burden are described in detail elsewhere (GBD 2015 DALYs and HALE Collaborators [@CR10]; GBD 2015 Disease and Injury Incidence and Prevalence Collaborators [@CR11]; GBD 2015 Mortality and Causes of Death Collaborators [@CR12]; GBD 2015 Risk Factors Collaborators [@CR13]; Global Burden of Disease Cancer Collaboration et al. [@CR14]).

Briefly, to estimate cancer burden, we mapped all neoplasms as defined by the 10th revision of the International Statistical Classification of Diseases (ICD-10) to one of the 29 GBD cancer groups. Input data for cancer mortality estimates came from vital registry mortality and cancer registry incidence data. The latter were transformed to mortality estimates using separately modeled mortality-to-incidence ratios (MIR) (Global Burden of Disease Cancer Collaboration et al. [@CR14]). The raw data were processed to make them comparable and to account for "garbage codes", which are codes assigned to causes that are not usable from a public health perspective (Naghavi et al. [@CR001]). These causes were redistributed to the most likely underlying cause of death based on a regression model. Data were extracted at the most detailed level, by age group and sex, and mapped to the GBD cause list. Using a cause of death ensemble modeling (CODEm) approach with cause-specific covariates, we computed mortality estimates for each individual cause (Foreman et al. [@CR9]). These estimates were scaled to fit into an independently modeled all-cause mortality estimate using the algorithm CodCorrect (GBD 2015 Mortality and Causes of Death Collaborators [@CR12]). We transformed the final mortality estimates into incidence estimates using modeled MIR. Uncertainty from data sources and processing steps was propagated to the incidence estimates.

Cancer survival was calculated using a MIR-based scaling factor. We calculated 10-year prevalence of each cancer and each incidence cohort using these cancer survival estimates. The total prevalence was divided into four sequelae with variable disability weights: (1) diagnosis and treatment, (2) remission, (3) metastatic, and (4) terminal phase. We assumed a constant duration for sequelae (1), (3), and (4) for all countries over time. Duration of sequela (2) was the remaining prevalence after subtracting the duration of the fixed sequelae. We computed YLLs by multiplying deaths by the normative standard life expectancy at each age of death (GBD 2015 Mortality and Causes of Death Collaborators [@CR12]). For each sequela, YLDs were calculated by multiplying the prevalence of each sequela by its disability weight. Finally, DALYs were calculated by summing YLLs and YLDs.

To analyze the contribution of population aging, population growth, and changes in age-specific incidence rates (ASIR) to the absolute change of cancer incidence, we calculated two scenarios. In the first, the age structure, sex structure, and age-specific rates from 2005 were applied to the 2015 population. The difference between the total number of cases in 2005 and the hypothetical scenario were attributed to population growth. In the second, the age-specific rates from 2005 were applied to the age structure, sex structure, and 2015 population. The differences between the two scenarios were attributed to population aging. Differences between the total number of cases in 2015 and the second hypothetical scenario were attributed to changes in the age-specific rates.

The 22 EMR countries were grouped according to per capita gross national income (GNI) into low-income countries (LICs) (Afghanistan, Djibouti, Somalia, and Yemen); middle-income countries (MICs) (Egypt, Iran, Iraq, Jordan, Lebanon, Libya, Morocco, Pakistan, Palestine, Sudan, Syria, and Tunisia); and high-income countries (HICs) (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates). LICs were defined as those having a per capita GNI of \$1045 or less, MICs as those with a per capita GNI between \$1046 and \$12,735, and HICs as countries with per capita GNI of \$12,736 or greater.

In this publication, all rates are reported per 100,000 person-years. We report 95% uncertainty intervals (UIs) for all estimates (listed in parentheses after the point estimates).

Results {#Sec3}
=======

Regional burden of cancer {#Sec4}
-------------------------

Between 2005 and 2015 in the EMR region, incident cancer cases increased by 46.1% (34.5--59.4%) from 495 (457--537) thousand in 2005 to 723 (661--790) thousand cases in 2015 (Table [1](#Tab1){ref-type="table"}). In 2015, cancer caused 379 (350--409) thousand deaths (Table [2](#Tab2){ref-type="table"}) and 11.7 million (10.8--12.7 million) DALYs, of which 3% were attributable to YLDs and 97% to YLLs (eFig. 1). Age-standardized DALY rates (ASDR) remained unchanged between 2005 and 2015: 2663.7 (2486.3--2861.0) in 2005, and 2605.3 (2404.8--2816.0) in 2015 (eTable 4).Table 1Decomposition Analysis of Cancer Incidence by Country in the Eastern Mediterranean Region, both sexes, 2005--2015 (Global Burden of Disease Study 2015, Eastern Mediterranean Countries, 2005--2015)LocationNumber of incident casesExpected number of cases in 2015Change in incident cases 2005--2015 in %Overall change in %20052015Given population growth aloneGiven population growth and agingDue to population growthDue to population ageingDue to change in incidence ratesEastern Mediterranean Region494,690722,646609,771670,38623.312.310.646.1Afghanistan25,01536,80933,40035,37533.57.95.747.2Bahrain66311051050121858.525.3−17.166.7Djibouti7721153879102013.818.317.349.4Egypt62,48987,85376,10680,68021.87.311.540.6Iran67,01995,01175,05488,51012.020.19.741.8Iraq28,59341,20838,47440,35434.66.63.044.1Jordan401661885677650441.420.6−7.954.1Kuwait141625442430270171.519.2−11.179.6Lebanon744613,27210,86711,93345.914.318.078.2Libya52057646563867628.321.617.046.9Morocco36,74353,37041,47548,93112.920.312.145.3Oman112725242016224078.819.925.2123.9Pakistan175,827254,242215,840233,15222.89.812.044.6Palestine210434792730305329.815.320.365.4Qatar529129014171281167.7−25.71.7143.7Saudi Arabia938415,72611,91214,35926.926.114.667.6Somalia720798629193897427.6−3.012.336.8Sudan20,55229,74025,87127,94025.910.18.844.7Syria793810,956813497532.520.415.138.0Tunisia14,02319,47115,59217,99811.217.210.538.8United Arab Emirates3268924766638585103.958.820.2182.9Yemen13,35219,95017,47218,37530.96.811.849.4 Table 2Incidence, deaths and disability-adjusted life years for all cancers and 29 cancer groups in the Eastern Mediterranean Region, both sexes, 2015 (Global Burden of Disease Study 2015, Eastern Mediterranean Region, 2015)CauseNumber of incident casesNumber of deathsNumber of DALYs (in thousands)MalesFemalesBothMalesFemalesBothMalesFemalesBothAll cancers groups309,240 (282,640--340,657)413,406 (361,086--467,300)722,646 (660,722--790,102)198,164 (181,894--217,561)180,929 (160,360--202,560)379,093 (350,252--408,580)5865 (5354--6474)5875 (5191--6608)11,740 (10,800--12,742)Lip and oral cavity cancer14,068 (10,664--18,701)15,358 (11,296--21,357)29,426 (23,752--36,473)4918 (4009--6069)4837 (3841--5943)9755 (8315--11,408)161 (127--203)151 (119--187)312 (263--368)Nasopharynx cancer3219 (2080--4681)1836 (1041--2849)5055 (3606--6940)1469 (1242--1776)825 (680--984)2294 (2006--2681)52 (43--63)30 (25--36)82 (71--97)Other pharynx cancer4394 (3516--5394)3593 (2915--4365)7988 (6914--9273)1654 (1410--1976)1391 (1165--1641)3045 (2679--3457)46 (40--55)40 (34--48)87 (76--99)Esophageal cancer8795 (7449--10,517)7992 (6474--9848)16,788 (14,577--19,253)9345 (8068--10,879)8396 (6823--10,239)17,741 (15,743--20,073)265 (223--317)251 (203--313)516 (452--595)Stomach cancer27,093 (24,235--30,565)17,725 (14,951--20,558)44,818 (40,719--49,095)17,462 (15,667--19,460)11,847 (9954--13,631)29,309 (26,728--31,947)441 (394--496)328 (264--387)769 (690--851)Colon and rectum cancer18,662 (16,276--21,216)17,150 (15,090--19,477)35,813 (32,240--39,507)13,268 (11,666--14,925)13,148 (11,498--14,918)26,416 (23,736--29,279)392 (335--450)373 (321--427)764 (678--859)Liver cancer14,660 (12,042--16,784)9908 (7418--11,788)24,568 (20,618--27,385)16,617 (13,869--18,735)10,747 (8232--12,290)27,365 (23,002--30,174)448 (347--513)292 (211--342)740 (588--823)Gallbladder and biliary tract cancer2383 (1983--2803)4543 (3731--5279)6926 (5941--7838)1985 (1673--2312)3853 (3161--4465)5839 (4973--6612)50 (41--59)98 (79--116)148 (124--169)Pancreatic cancer6283 (5762--6843)4885 (4393--5394)11,168 (10,419--11,995)7011 (6463--7643)5480 (4917--6100)12,491 (11,601--13,400)179 (164--196)129 (116--144)308 (285--331)Larynx cancer11,975 (10,284--14,128)2887 (2458--3493)14,862 (13,083--17,018)6477 (5676--7380)1612 (1345--1917)8090 (7222--9049)172 (150--199)46 (39--54)218 (193--245)Tracheal, bronchial and lung cancer37,681 (32,768--42,292)11,848 (10,591--13,321)49,530 (44,083--54,564)39,180 (34,316--43,815)11,831 (10,442--13,380)51,012 (45,430--56,191)1013 (879--1144)317 (277--364)1330 (1171--1475)Malignant skin melanoma3021 (2072--3909)2733 (2326--3212)5755 (4863--6883)617 (407--773)514 (452--591)1131 (947--1322)20 (14--27)16 (14--19)36 (31--44)Non-melanoma skin cancer9359 (8443--10,285)4697 (4165--5264)14,056 (12,711--15,383)1015 (921--1117)314 (272--361)1330 (1223--1449)27 (24--30)9 (7--10)36 (33--39)Breast cancer2058 (1810--2359)177,389 (148,702--207,371)179,447 (150,924--209,304)463 (408--530)38,117 (32,305--44,251)38,581 (32,795--44,698)14 (12--16)1314 (1101--1546)1328 (1115--1561)Cervical cancer--19,634 (14,721--25,505)19,634 (14,721--25,505)--7878 (6158--9928)7878 (6158--9928)--251 (192--323)251 (192--323)Uterine cancer--14,337 (11,576--17,621)14,337 (11,576--17,621)--6857 (5641--8076)6857 (5641--8076)--193 (157--228)193 (157--228)Ovarian cancer--10,946 (9024--13,395)10,946 (9024--13,395)--6855 (5953--7833)6855 (5953--7833)--235 (201--271)235 (201--271)Prostate cancer27,533 (20,349--34,378)--27,533 (20,349--34,378)13,861 (10,420--17,187)--13,861 (10,420--17,187)243 (180--297)--243 (180--297)Testicular cancer3143 (2315--4266)--3143 (2315--4266)1010 (792--1299)--1010 (792--1299)52 (40--68)--52 (40--68)Kidney cancer5465 (4635--6345)2856 (2463--3279)8321 (7364--9305)3497 (3046--3942)1741 (1505--2039)5239 (4699--5834)110 (96--125)60 (52--71)170 (152--190)Bladder cancer23,449 (20,144--27,360)6404 (5411--7716)29,853 (26,404--33,966)9452 (8524--10,545)3151 (2723--3587)12,604 (11,527--13,821)217 (194--244)73 (63--83)289 (263--320)Brain and nervous system12,805 (9708--15,710)11,045 (9432--12,702)23,851 (20,099--27,075)10,333 (7909--12,510)8395 (7355--9338)18,729 (16,185--20,983)427 (321--525)352 (300--392)779 (666--881)Thyroid cancer3654 (2966--4357)7536 (6026--9477)11,191 (9589--13,565)565 (484--688)1112 (925--1352)1678 (1478--2000)17 (14--20)32 (26--39)49 (42--58)Mesothelioma839 (724--1015)260 (215--339)1099 (964--1313)794 (717--909)299 (245--360)1093 (987--1243)24 (22--28)10 (8--12)34 (30--39)Hodgkin lymphoma3247 (2539--4383)2372 (1488--3502)5619 (4436--7142)1176 (932--1649)811 (547--1245)1987 (1655--2658)50 (39--70)36 (23--53)86 (70--114)Non-Hodgkin lymphoma16,818 (14,017--20,617)14,549 (9501--18,687)31,367 (24,638--36,975)6745 (5684--8121)5999 (4194--7470)12,744 (10,225--14,857)251 (209--305)216 (146--274)466 (365--553)Multiple myeloma2693 (2323--3268)2643 (2205--3157)5336 (4694--6150)2318 (2038--2761)2395 (2028--2834)4714 (4196--5411)66 (57--80)67 (56--80)132 (116--154)Leukemia26,878 (23,330--31,115)20,800 (17,703--24,679)47,679 (42,513--53,365)14,627 (13,388--16,013)11,206 (10,045--12,467)25,833 (24,105--27,809)637 (579--705)498 (445--557)1135 (1053--1232)Other neoplasms19,054 (15,995--23,621)17,468 (14,692--21,110)36,523 (32,170--42,695)12,292 (10,537--15,191)11,306 (9694--13,334)23,599 (20,803--27,877)494 (418--603)459 (389--546)953 (840--1103)

Regional age and sex variations in cancer burden {#Sec5}
------------------------------------------------

Females had higher ASIR in 2015 than males, with 199.6 (175.7--224.5) in females and 163.3 (150.2--178.7) in males (Table [3](#Tab3){ref-type="table"}). Age-standardized mortality rate (ASMR) was higher in males compared to females at 113.8 (105.0--124.0) versus 95.8 (85.4--106.7), respectively. In females, breast cancer, leukemia, and cervical cancer were the most common incident cancers with 177 (149--207) thousand, 21 (18--25) thousand, and 20 (15--26) thousand cases, respectively (Table [2](#Tab2){ref-type="table"}). The three cancers responsible for most cancer deaths in females were breast cancer with 38 (32--44) thousand deaths, colon and rectal cancer with 13 (11--15) thousand deaths, and stomach cancer with 12 (10--14) thousand deaths. The top three causes of DALYs in females were breast cancer with 1.3 (1.1--1.5) million DALYs, leukemia with 498 (445--557) thousand DALYs, and other neoplasms with 459 (339--546) thousand DALYs (Table [2](#Tab2){ref-type="table"}).Table 3Age-standardized incidence, mortality and DALY rates per 100,000 for the Eastern Mediterranean Region and its 22 countries, both sexes, 2015 (Global Burden of Disease Study 2015, Eastern Mediterranean Countries, 2015)LocationAge-standardized incidence rateAge-standardized mortality rateAge-standardized DALY rateMalesFemalesBothMalesFemalesBothMalesFemalesBothEastern Mediterranean Region163 (150--179)200 (176--225)180 (166--195)114 (105--124)96 (85--107)104 (97--112)2651 (2435--2915)2583 (2287--2897)2605 (2404--2816)Afghanistan178 (127--237)345 (171--642)259 (161--411)156 (109--205)177 (102--276)165 (112--222)3546 (2355--4889)5066 (2618--8449)4260 (2634--6153)Bahrain134 (105--168)156 (122--196)138 (117--162)88 (69--107)70 (56--85)77 (66--89)1752 (1385--2170)1776 (1395--2221)1710 (1453--2003)Djibouti201 (103--409)221 (105--528)210 (113--388)158 (80--311)129 (61--301)142 (75--257)3972 (1896--8438)3634 (1696--8796)3783 (1951--7187)Egypt146 (135--165)137 (126--149)139 (131--151)100 (94--111)65 (62--71)81 (77--87)2437 (2299--2619)1846 (1740--1973)2113 (2022--2229)Iran208 (166--260)135 (104--175)173 (146--205)123 (98--150)69 (52--89)97 (81--113)2650 (2080--3338)1704 (1286--2243)2190 (1825--2595)Iraq185 (129--243)254 (178--344)220 (172--280)138 (95--176)117 (86--156)126 (101--155)3340 (2303--4462)3329 (2385--4498)3318 (2625--4180)Jordan153 (131--179)145 (115--178)147 (129--169)98 (84--114)64 (53--76)80 (71--90)2193 (1888--2580)1708 (1423--2039)1939 (1713--2179)Kuwait139 (118--167)179 (148--214)156 (139--176)71 (60--84)68 (56--82)70 (62--79)1403 (1181--1664)1523 (1256--1815)1453 (1292--1644)Lebanon284 (192--391)246 (165--341)262 (195--336)158 (104--218)110 (73--146)133 (99--170)3302 (2179--4603)2715 (1771--3746)2995 (2238--3864)Libya226 (187--276)160 (133--194)189 (166--218)157 (128--191)91 (74--110)121 (104--139)3326 (2703--4039)2245 (1815--2752)2752 (2360--3181)Morocco180 (126--258)210 (138--296)195 (151--252)140 (98--201)108 (72--148)122 (96--159)3019 (2053--4385)2690 (1776--3789)2844 (2205--3728)Oman121 (97--143)118 (98--144)116 (99--132)74 (58--87)58 (47--69)66 (55--75)1564 (1237--1867)1397 (1115--1711)1469 (1220--1688)Pakistan153 (127--185)278 (213--350)214 (180--253)109 (91--131)126 (97--155)117 (100--135)2878 (2374--3537)3498 (2678--4319)3182 (2713--3685)Palestine149 (115--192)153 (117--205)150 (122--182)116 (87--146)71 (55--92)92 (74--110)2816 (2094--3653)2015 (1546--2663)2396 (1925--2898)Qatar144 (110--189)180 (136--226)150 (122--183)90 (67--118)79 (59--99)84 (67--104)1667 (1251--2170)1932 (1452--2463)1700 (1382--2109)Saudi Arabia104 (85--128)92 (73--113)96 (82--111)67 (60--77)43 (39--49)55 (50--60)1300 (1154--1490)992 (881--1124)1134 (1033--1251)Somalia144 (62--304)257 (76--608)202 (69--449)130 (53--270)166 (44--382)149 (49--319)3267 (1266--7474)4751 (1262--11,703)4031 (1274--9504)Sudan136 (97--185)163 (97--241)149 (110--195)111 (80--157)85 (54--122)97 (73--125)2485 (1719--3601)2216 (1338--3228)2338 (1722--3074)Syria103 (84--124)105 (86--126)103 (90--118)76 (61--92)54 (44--63)64 (55--72)1653 (1343--1972)1345 (1099--1592)1487 (1288--1685)Tunisia224 (169--289)164 (117--213)190 (151--231)163 (122--210)76 (55--100)115 (90--141)3445 (2596--4545)1878 (1356--2479)2610 (2057--3170)United Arab Emirates213 (155--290)226 (158--310)207 (157--270)106 (81--139)85 (65--115)97 (76--123)2191 (1621--2891)2279 (1694--3069)2145 (1651--2720)Yemen131 (85--198)201 (114--353)167 (101--268)109 (72--168)103 (59--164)106 (65--164)2445 (1529--3909)2753 (1558--4552)2601 (1527--4180)

The most common incident cancers in males in 2015 were tracheal, bronchus, and lung cancer (TBL) with 38 (33--42) thousand cases, followed by prostate cancer and stomach cancer, with 28 (20--34) thousand and 27 (24--31) thousand cases, respectively. These cancers accounted for 30% of the incidence of all cancers. The most common causes of cancer deaths in males were TBL, stomach cancer, and liver cancer with 39 (34--44) thousand, 17 (16--19) thousand, and 17 (14--19) thousand deaths, respectively. The top three causes of DALYs in males were TBL with 1.0 (0.8--1.1) million DALYs, leukemia with 637 (579--705) thousand DALYs, and other neoplasms with 494 (418--603) thousand DALYs (Table [2](#Tab2){ref-type="table"}).

In children aged 0--14 years, the most common cancers were leukemia, other neoplasms, and cancer of the brain and nervous system (Fig. [1](#Fig1){ref-type="fig"}). These cancers were also the ones responsible for most childhood cancer deaths (Fig. [2](#Fig2){ref-type="fig"}). In adolescents and young adults (ages 15--39 years), the most common cancers were breast cancer, followed by leukemia and other neoplasms. These cancers were also main causes of death in this age group.Fig. 1Age-specific contribution of cancer groups to total cancer incidence in the Eastern Mediterranean Region, both sexes, 2015 (Global Burden of Disease Study 2015, Eastern Mediterranean Region, 2015) Fig. 2Age-specific contribution of cancer groups to total cancer mortality in the Eastern Mediterranean Region, both sexes, 2015. (Global Burden of Disease Study 2015, Eastern Mediterranean Region, 2015)

National cancer incidence, mortality, and burden {#Sec6}
------------------------------------------------

In 2015, Lebanon had the highest ASIR for all cancers at 261.9 (194.6--336.2), followed by Afghanistan at 258.8 (161.3--411.3), and Iraq at 219.9 (172.2--279.8) (Table [3](#Tab3){ref-type="table"}). ASMRs were highest in Afghanistan at 165.0 (111.5--221.7), followed by Somalia at 148.6 (49.1--319.1), and Djibouti at 142.0 (75.4--256.6). Those three countries also had the highest ASDRs in 2015. Saudi Arabia, Syria, and Oman had the lowest ASIRs in 2015 with 95.6 (82.3--111.5), 103.5 (89.9--117.8), and 115.8 (98.5--131.8), respectively. Those countries also had the lowest ASMR with 54.8 (50.1--60.0), 64.0 (55.0--72.4), and 66.0 (55.2--74.7), respectively. Along with Kuwait, these countries had the lowest ASDRs in 2015 as well.

Burden of different cancer groups {#Sec7}
---------------------------------

Excluding the "other neoplasms" group, five cancers, namely breast cancer, TBL, leukemia, stomach cancer, and colon and rectal cancer ranked highest in terms of incident cases in the region. Breast cancer had the highest ASIR in the EMR in 2015 with 42.3 (35.7--48.9) cases. It also had the second-highest ASMR after TBL in the region with 9.9 (8.5--11.3) deaths (eTable 1). There were 179 (151--209) thousand new cases in 2015, 39 (33--45) thousand deaths, and 1.3 (1.1--1.6) million DALYs caused by breast cancer (Table [2](#Tab2){ref-type="table"}). Only 1% (2058 cases) of breast cancer cases occurred in males (Table [2](#Tab2){ref-type="table"}). Nine percent of all DALYs caused by breast cancer came from YLDs (eFigure 1).

In 2015, TBL had the second highest ASIR the region with 13.9 (12.5--15.2). It was the leading cause of cancer deaths and DALYs in the region with 51 (44--55) thousand incident cases, 51 (45--56) thousand deaths, and 1.3 (1.2--1.5) million DALYs. Seventy-six percent of new cases and deaths occurred in males. Only 1% of DALYs came from YLDs.

There were 48 (43--53) thousand new cases of leukemia in 2015 in the region and 26 (24--28) thousand deaths, making it the third most common cancer in the region. Leukemia caused 1.1 (1.1--1.2) million DALYs, with 97% coming from YLLs.

Stomach cancer had the fourth-highest ASIR the region in 2015 at 13.2 (12.0--14.4), but ranked first in Afghanistan with 40.5 (26.1--55.0) and second in Iran, Yemen, and Sudan with 29.1 (24.0--35.7), 19.0 (11.6--29.4), and 18.1 (13.2--23.6), respectively (Online Appendix Data). There were 45 (41--49) thousand cases in 2015, 29 (27--32) thousand deaths, and 769 (690--851) thousand DALYs, of which only 2% came from YLDs. Sixty percent of incident cases, 60% of deaths, and 57% of DALYs occurred in males.

Colon and rectum cancer was the sixth most frequent cancer in the region in 2015 with 36 (32--40) thousand incident cases, 26 (24--29) thousand deaths, and 764 (678--859) thousand DALYs. It was the second most frequent incident cancer in 2015 in Jordan, Kuwait, Lebanon, Libya, Qatar, and Saudi Arabia.

Drivers of change in cancer incidence {#Sec8}
-------------------------------------

Between 2005 and 2015, the overall change in the number of incident cancer cases ranged between 36.8% in Somalia and 182.9% in the UAE (Table [1](#Tab1){ref-type="table"}). High-income EMR countries in addition to Lebanon experienced the largest increase in cancer incidence, which was mainly driven by population growth in all countries. Population aging was responsible for 12% of the increase in incident cancer cases in the region in total, ranging from −25.7% in Qatar to 58.8% in the UAE. Change in age-specific incident rates ranged between −17.1% in Bahrain and 25.2% in Oman relative to the overall change in incident cases (Table [1](#Tab1){ref-type="table"}).

Discussion {#Sec9}
==========

In 2015, cancer was responsible for 9.4% (8.9--9.9%) of all deaths and 5.1% (4.6--5.8%) of all DALYs in the EMR countries compared to 15.7% (15.5--15.9%) of deaths and 8.5% (7.8--9.2%) of all DALYs at the global level (GBD 2015 DALYs and HALE Collaborators [@CR10]; GBD 2015 Mortality and Causes of Death Collaborators [@CR12]). This puts cancer as the third-leading cause of death and the eighth-leading cause of DALYs in the EMR. In EMR countries, cancer deaths between 2005 and 2015 have increased by 32.9%. Females experienced higher cancer incidence in the EMR but lower cancer deaths compared to males, which can be explained by less aggressive cancers (breast, cervical) being among the top cancers in females compared to males (lung, stomach). Age-standardized cancer incidence varied substantially between EMR countries with infection-related cancers playing a more important role in low- and low-middle income countries (e.g., stomach cancer having the highest ASIR in Afghanistan, Iran, Yemen, and Sudan, and cancers related to low physical activity and cancers with strong lifestyle-related risk factors such as colorectal cancer being more common in middle- and high-income EMR countries such as Lebanon, the UAE, and Libya).

Given this alarming trend and the substantial contribution of cancer to the disease burden in EMR countries, cancer control has to be among the top health policy priorities. Compared to other studies (Aljurf et al. [@CR4]; Abdel-Razeq et al. [@CR1]; Kulhánová et al. [@CR19]) analyzing cancer burden in the EMR countries, the GBD study provides analyses of all diseases over time, which means that cancer can be viewed in the context of other health priorities. Kulhánová et al. recently published an analysis using GLOBOCAN data to analyze the cancer burden in the EMR (Kulhánová et al. [@CR19]). Because of different methods to estimate incidence and mortality as well as few high-quality data sources for cancer incidence and mortality in the EMR, GBD estimates for incidence differ between 50% fewer incident cases (for Syria) to 215% more incident cases (for the UAE). For mortality, GBD estimates range from 56% fewer deaths in Syria to 153% more deaths in the UAE (eTable 4). Whereas the GLOBOCAN methodology starts with estimating cancer incidence and then for most EMR countries models survival to estimate mortality (Ferlay et al. [@CR8]), GBD uses cancer registry incidence-based mortality estimates as well as vital registration data to model mortality and then uses these mortality estimates as well as modeled MIR to estimate cancer incidence. An advantage of the GBD study is the ability to compare trends over time, which allows for analysis of the effects of the demographical and epidemiological transition, and also the effectiveness of public health policies. The discrepancies between GLOBOCAN and GBD estimates underscore the need for better data to assess cancer burden in the EMR countries. Few high-quality population-based cancer registries exist in the EMR, with the Global Initiative for Cancer Registry Development (GICR) actively promoting further development of cancer registries (International Agency for Research on Cancer (IARC) [@CR17]). At the same time, strengthening of vital registration systems and integration of surveillance systems for other non-communicable diseases is needed in the region. Until better data become available, model-based estimates have to be used to guide local policy.

Two significant international statements address the threat of non-communicable diseases and propose interventions as well as metrics to measure success. The SDGs, as the successors of the Millennium Development Goals, which shaped public health policy for 15 years, now include non-communicable diseases (NCDs) in the third goal, "by 2030, reduce by one-third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being" (United Nations [@CR28]). Control of NCDs has also been targeted in the WHO Global Action Plan for Prevention and Control of NCDs 2013--2020 (World Health Organization [@CR31]). Our study shows that substantial efforts are required in most EMR countries to meet the SDG targets of reducing cancer mortality. Culprits for the disappointing pace of cancer control to date can be found in all aspects of cancer care, from primary prevention and screening, to early diagnosis, access to cancer treatment, tertiary prevention, and palliative care (World Health Organization [@CR32]).

We have seen exciting advances in our understanding of cancer and resulting treatment approaches in the last decade. However, the increasing cancer burden due to an aging population and the exploding costs associated with complex cancer treatments are leading to unacceptable increases in health care expenditure, which will be impossible to sustain for most countries (Kelly and Smith [@CR18]). For this reason, risk factor reduction has to be a priority for any cancer control effort. The top five risk factors identified in GBD as contributing to cancer mortality in the EMR are tobacco, dietary risks, high body mass index, occupational risks, and air pollution (GBD 2015 Risk Factors Collaborators [@CR13]). With lung cancer being the second-leading cause of cancer death in the region, tobacco control has to be the top priority. Health hazards of cigarette smoking are well established. However, other forms of tobacco consumption such as chewing and shisha (waterpipe) smoking also lead to an increased risk of death, mainly due to cancer (Etemadi et al. [@CR7]). All countries in the EMR with the exception of Somalia and Palestine have signed the WHO Framework Convention on Tobacco Control (WHO FCTC), and all countries except Morocco have ratified it. However, in many EMR countries, smoking rates have not declined, with certain forms of tobacco consumption such as shisha smoking even rising (Maziak et al. [@CR21]). Secondhand smoking is not restricted in most countries in the EMR despite the FCTC recommendations (Heydari et al. [@CR16]).

Obesity and lack of physical activity are risk factors that also follow a dangerous trend, with obesity prevalence rising in many EMR countries to concerning levels (Ng et al. [@CR23]). Obesity has been proven to be a risk factor for esophageal adenocarcinoma, colon, rectal, kidney, and pancreas cancer, gallbladder cancer in females, and postmenopausal breast, ovarian, and uterine cancers (Lauby-Secretan et al. [@CR20]). Physical inactivity has been linked to an increased risk for cancer, especially colon and breast cancer (American Institute for Cancer Research and World Cancer Research Fund [@CR6]). For both sexes combined, breast cancer is the most common incident cancer in every EMR country, and colorectal cancer is among the top four most common cancers in all high-income EMR countries as well as all middle-income EMR countries except for Iran, Pakistan, Sudan, Syria, Egypt, Morocco, and Iraq. This stresses the importance of health intervention programs and environmental policies to increase physical activity and healthy dietary habits.

Other important strategies for primary prevention include vaccination against human papillomavirus (HPV) for cervical cancer prevention, as well as hepatitis B vaccination and treatment of hepatitis B and C, especially in countries with high hepatitis C prevalence such as Egypt, where liver cancer is the leading cause of cancer death (Alavian and Haghbin [@CR3]). In the case of liver cancer, screening of high-risk groups has also been recommended by the National Comprehensive Cancer Network (NCCN) as a core intervention in the resources stratified guidelines (National Comprehensive Cancer Network [@CR22]). However, early detection is dependent on a functioning primary care system as well as universal access to care, the developments of both of which are hampered by fragmented care systems, lack of strategic planning, an unregulated private sector, as well as political turmoil in some EMR countries (Regional Committee for the EM/RC57/Tech.Disc.1 and Eastern Mediterranean [@CR24]).

An emphasis on addressing cancer once it becomes clinically symptomatic rather than on detecting it early is also apparent by the lack of population-wide cancer screening programs. Effective screening is currently available for cervical cancer, colorectal cancer, breast cancer, oral cancer, and stomach cancer (in high-risk populations) (Sankaranarayanan [@CR26]). With breast and cervical cancer being among the most common cancers in females in every EMR country, cancer screening should be among the prioritized prevention efforts (Goldie et al. [@CR15]; Yip et al. [@CR33]). For screening programs to be successful at the population level, strategic implementation should be coordinated at the national level and include educational components, as well monitoring and evaluation to ensure success and sustainability. Opportunistic screening programs in the past have been hampered by low participation rates due to anxiety, misperception of the screening's purpose, and a general sense that cancer at any stage is a death sentence (Al Mulhim et al. [@CR2]; Al-Zalabani et al. [@CR5]). Civil engagement through education and advocacy is therefore an important pillar of successful and sustainable screening programs.

Cancer treatment programs depend on multidisciplinary approaches that are often unavailable in EMR countries. Laboratory services, pathology, radiology, oncology nursing, surgery, medical and radiation oncology, pharmacology, transfusion services, nutritional and psychosocial support services, as well as palliative care and hospice services are the core disciplines required to provide cancer care. There is a lack of human capital for many, if not of all, of these disciplines, which will require continued and coordinated efforts to train local staff and ensure retention (World Health Organization [@CR32]).

Another important factor contributing to poor health in some EMR countries is war, leading to a large number of displaced people, disruption in care structures and supplies, lack of qualified healthcare personnel, and financial strains on patients and healthcare systems in countries with large refugee populations (Spiegel et al. [@CR27]; Sahloul et al. [@CR25]). Innovative solutions to monitor disease burden in these most vulnerable populations have been proposed and include web-based cancer registries with linkages between countries (Spiegel et al. [@CR27]). Approaches during humanitarian emergencies to prevent and treat cancer and other diseases requiring complex care systems include clear referral guidelines as provided by the United Nations High Commissioner for Refugees (UNHCR), as well as financing systems such as health insurance or social security (United Nations High Commissioner for Refugees [@CR29], [@CR30]).

Limitations {#Sec10}
-----------

Our data sources to estimate cancer burden in the EMR are vital registration and cancer registry data. The GBD study tries to identify and utilize all available data sources in the estimation process. However, data sources in low- and middle-income countries are scarce, and causes of death and cancer registration is not a routine procedure in many health care systems. Even when civil registration exits, war or civil unrest can interrupt routine data collection. In the absence of reliable data, our estimates are largely driven by regional trends and the selection of model covariates which lead consequently to wider uncertainty intervals and time trends that are therefore often non-significant. Furthermore, miscoding of causes of death---as the so-called garbage codes---in vital registration data can influence both our mortality estimates and incidence estimates. Misclassifying metastatic sites (e.g., lung, liver, bone) as the primary cancer site or as second cancers is another potential source of bias. This is particularly true in countries with low-quality registration and limited diagnostic sources.

Conclusions {#Sec11}
-----------

Cancer is among the leading causes of death and DALYs in most EMR countries. Prioritization of different aspects of the cancer control continuum depends on local health infrastructure as well as disease epidemiology. Given the dramatic increase in cancer cases and deaths over the last decade, all stakeholders including health policymakers, care providers, and the general public need to actively engage to define these priorities and work together on implementation of evidence-based cancer control strategies.
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